In Q1 of 2019 CARE™ conducted a Needs Assessment on Mantle Cell Lymphoma (MCL) that was directed at hematologists/oncologists across Canada. The aim of this CARE™ program was to gather feedback on the current state of MCL management in Canada, while also identifying potential areas of need or gaps in knowledge.
The results of this CARE™ Needs Assessment will be presented in two follow-up waves. This report (Wave 1) focuses on the initial management of transplant ineligible MCL patients, while Wave 2 (scheduled for release in Q3 of 2019) will focus on the transplant eligible.
Both Waves will be accompanied by CARE™ Faculty Perspectives as well as a case study.
CARE™ Hematology Faculty who have contributed to this report:
Dr. Diego Villa (BC Cancer)